Real-world outcomes on platinum-containing chemotherapy for
advanced non-small cell lung cancer
overall survival
platinum-containing chemotherapy
sensitizing EGFR mutation
subsequent therapy
tyrosine kinase inhibitor
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2024
2024
Historique:
received:
29
08
2023
accepted:
18
03
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
3
5
2024
Statut:
epublish
Résumé
Front-line therapy with an EGFR tyrosine kinase inhibitor (TKI) is the standard of care for treating patients with advanced nonsquamous NSCLC with the common sensitizing This retrospective study used a nationwide electronic health record-derived deidentified database to select adult patients with advanced nonsquamous NSCLC, evidence of The two cohorts included two-thirds women (65%-66%) and 57%-58% nonsmokers; median ages were 66 and 65 years in pemetrexed-platinum and platinum cohorts, respectively. Median OS was 10.3 months (95% CI, 8.1-13.9) from pemetrexed-platinum initiation and 12.4 months (95% CI, 10.2-15.2) from platinum initiation; 12-month survival rates were 48% and 51%, respectively; 260 patients (84%) had died by the end of the study. The suboptimal survival outcomes recorded in this study demonstrate the unmet need to identify more effective subsequent treatment regimens for patients with
Sections du résumé
Background
UNASSIGNED
Front-line therapy with an EGFR tyrosine kinase inhibitor (TKI) is the standard of care for treating patients with advanced nonsquamous NSCLC with the common sensitizing
Methods
UNASSIGNED
This retrospective study used a nationwide electronic health record-derived deidentified database to select adult patients with advanced nonsquamous NSCLC, evidence of
Results
UNASSIGNED
The two cohorts included two-thirds women (65%-66%) and 57%-58% nonsmokers; median ages were 66 and 65 years in pemetrexed-platinum and platinum cohorts, respectively. Median OS was 10.3 months (95% CI, 8.1-13.9) from pemetrexed-platinum initiation and 12.4 months (95% CI, 10.2-15.2) from platinum initiation; 12-month survival rates were 48% and 51%, respectively; 260 patients (84%) had died by the end of the study.
Conclusion
UNASSIGNED
The suboptimal survival outcomes recorded in this study demonstrate the unmet need to identify more effective subsequent treatment regimens for patients with
Identifiants
pubmed: 38699642
doi: 10.3389/fonc.2024.1285280
pmc: PMC11063374
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1285280Informations de copyright
Copyright © 2024 Halmos, Rai, Min, Hu, Chirovsky, Shamoun and Zhao.
Déclaration de conflit d'intérêts
BH reports grants from Boehringer Ingelheim, Astra Zeneca, Merck, BMS, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GSK, Beigene, and Janssen; consulting fees from AstraZeneca, Boehringer Ingelheim, Janssen, Takeda, Merck, BMS, Genentech, Pfizer, Eli-Lilly, Arcus, and Merus; and participation in a Data Safety Monitoring Board or Advisory Board for TPT, BMS, Apollomics, Nuvalent, and Merck. PR, JM, XH, DC, MS, and BZ report full-time employment with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and stock ownership of Merck & Co., Inc., Rahway, NJ, USA. The authors declare that this study received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Employees of the funder participated in the study design; in the collection, analysis, and interpretation of data; in the writing of this article; and in the decision to submit the article for publication.